Akèy › Limfom Difize Gwo Selil B › New York
Etid klinik pou Limfom Difize Gwo Selil B nan New York
31 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan New York.
Vil nan New York
- New York City21 etid
- Greenburgh8 etid
- Buffalo6 etid
- Queens5 etid
- Rochester5 etid
- Staten Island3 etid
- New Rochelle3 etid
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Roswell Park Cancer Institute, Buffalo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Roswell Park Comprehensive Cancer Center, Buffalo
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Stony Brook University Hospital, Stony Brook
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06091865A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- New York Medical College ( Site 0113), Valhalla
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Roswell Park Cancer Institute ( Site 0192), Buffalo
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208), Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- New York Oncology Hematology, P.C. ( Site 0129), Albany
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
- New York Cancer and Blood Specialists ( Site 9000), Shirley
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Columbia University, New York
- University of Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- New York Oncology Hematology, P.C., Albany
- Hematology Oncology Associates of Central New York, East Syracuse
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
- University of Rochester Medical Center, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273A Study of ARC-02 in B-cell NHL
- NYU Langone, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Roswell Park Comprehensive Cancer Center, Buffalo
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Roswell Park Comprehensive Cancer Center, Buffalo
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- ak 1 plis
Ap rekriteFaz 2
Laj 65 a 80 · Tout sèks · Mizajou Jul 22, 2026 · NCT06765317Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
- Roswell Park Cancer Institute, Buffalo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT06863402DALY II USA/ MB-CART2019.1 for DLBCL
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center - Moses Campus, The Bronx
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05077527Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
Ap rekriteFaz 1/2
Laj 12 a 70 · Tout sèks · Mizajou Apr 15, 2026 · NCT04491370Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2026 · NCT04512716Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
- Columbia University, New York
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jan 23, 2026 · NCT06693830A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 18, 2025 · NCT06736613A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
- Wilmot Cancer Institute, Rochester
Ap rekriteFaz 2
Laj 70 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT06828991Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 9, 2025 · NCT05940272Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- New York Medical College, Valhalla
Ap rekriteFaz 2
Laj 3 a 31 · Tout sèks · Mizajou Aug 8, 2025 · NCT02393157Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 26, 2024 · NCT06238648Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.